| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 26 | 2025 | 1409 | 1.840 |
Why?
|
| Pathology | 9 | 2018 | 36 | 1.730 |
Why?
|
| Pathologists | 4 | 2017 | 30 | 1.650 |
Why?
|
| Amyotrophic Lateral Sclerosis | 8 | 2024 | 189 | 1.330 |
Why?
|
| Internship and Residency | 9 | 2017 | 1252 | 1.300 |
Why?
|
| Biomarkers, Tumor | 14 | 2024 | 1683 | 1.160 |
Why?
|
| Pathology, Clinical | 3 | 2017 | 24 | 1.070 |
Why?
|
| Meningioma | 7 | 2008 | 140 | 1.030 |
Why?
|
| Professionalism | 2 | 2017 | 51 | 0.990 |
Why?
|
| Pituitary Neoplasms | 4 | 2016 | 83 | 0.980 |
Why?
|
| Immunohistochemistry | 16 | 2017 | 1723 | 0.960 |
Why?
|
| DNA-Binding Proteins | 11 | 2024 | 1997 | 0.850 |
Why?
|
| Pathology, Surgical | 5 | 2014 | 21 | 0.840 |
Why?
|
| Education, Medical, Graduate | 7 | 2018 | 564 | 0.830 |
Why?
|
| Glioblastoma | 10 | 2024 | 374 | 0.810 |
Why?
|
| Hemangioblastoma | 3 | 2010 | 12 | 0.730 |
Why?
|
| Electrodes, Implanted | 2 | 2014 | 175 | 0.720 |
Why?
|
| Attitude of Health Personnel | 2 | 2017 | 722 | 0.700 |
Why?
|
| Meningeal Neoplasms | 4 | 2007 | 215 | 0.680 |
Why?
|
| Nervous System Diseases | 3 | 2014 | 410 | 0.660 |
Why?
|
| Spinal Cord | 6 | 2021 | 274 | 0.580 |
Why?
|
| Basal Forebrain | 2 | 2016 | 32 | 0.560 |
Why?
|
| Employment | 1 | 2017 | 68 | 0.540 |
Why?
|
| Job Satisfaction | 1 | 2017 | 99 | 0.530 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2009 | 215 | 0.520 |
Why?
|
| Deep Brain Stimulation | 2 | 2014 | 431 | 0.520 |
Why?
|
| Chemistry, Clinical | 1 | 2016 | 13 | 0.510 |
Why?
|
| Humans | 93 | 2025 | 132373 | 0.510 |
Why?
|
| Alzheimer Disease | 5 | 2022 | 865 | 0.490 |
Why?
|
| Oligodendroglia | 1 | 2016 | 79 | 0.490 |
Why?
|
| Middle Aged | 38 | 2025 | 28895 | 0.470 |
Why?
|
| Dependovirus | 1 | 2016 | 154 | 0.460 |
Why?
|
| Aged | 33 | 2025 | 21386 | 0.440 |
Why?
|
| Clinical Competence | 6 | 2015 | 1071 | 0.440 |
Why?
|
| Health Services | 1 | 2015 | 71 | 0.440 |
Why?
|
| Genetic Therapy | 2 | 2016 | 720 | 0.430 |
Why?
|
| Ependymoma | 4 | 2012 | 176 | 0.420 |
Why?
|
| Educational Measurement | 1 | 2016 | 329 | 0.420 |
Why?
|
| Autopsy | 6 | 2014 | 120 | 0.410 |
Why?
|
| Genetic Vectors | 2 | 2016 | 927 | 0.410 |
Why?
|
| Adult | 34 | 2025 | 31624 | 0.410 |
Why?
|
| Female | 54 | 2025 | 70809 | 0.400 |
Why?
|
| Gliosis | 2 | 2010 | 33 | 0.400 |
Why?
|
| Hypothalamus | 1 | 2014 | 210 | 0.400 |
Why?
|
| Astrocytoma | 4 | 2012 | 111 | 0.400 |
Why?
|
| C9orf72 Protein | 3 | 2023 | 51 | 0.400 |
Why?
|
| Male | 48 | 2025 | 65072 | 0.370 |
Why?
|
| Health Care Costs | 1 | 2015 | 407 | 0.350 |
Why?
|
| Brain | 8 | 2021 | 3200 | 0.350 |
Why?
|
| S100 Calcium Binding Protein G | 2 | 2007 | 24 | 0.340 |
Why?
|
| Diagnosis, Differential | 11 | 2016 | 1964 | 0.340 |
Why?
|
| Ventral Thalamic Nuclei | 1 | 2010 | 16 | 0.320 |
Why?
|
| Genomics | 2 | 2018 | 1652 | 0.320 |
Why?
|
| Cerebellar Neoplasms | 2 | 2012 | 461 | 0.320 |
Why?
|
| Neurons | 4 | 2024 | 2017 | 0.320 |
Why?
|
| Craniopharyngioma | 1 | 2010 | 34 | 0.320 |
Why?
|
| Histological Techniques | 1 | 2009 | 21 | 0.320 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2011 | 189 | 0.310 |
Why?
|
| Receptors, Estrogen | 2 | 2016 | 741 | 0.310 |
Why?
|
| Intraoperative Period | 2 | 2007 | 71 | 0.310 |
Why?
|
| Isocitrate Dehydrogenase | 3 | 2018 | 82 | 0.310 |
Why?
|
| Neurilemmoma | 2 | 2010 | 46 | 0.310 |
Why?
|
| Central Nervous System | 1 | 2011 | 284 | 0.310 |
Why?
|
| Essential Tremor | 1 | 2010 | 94 | 0.290 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2010 | 246 | 0.290 |
Why?
|
| Immunotherapy | 3 | 2022 | 748 | 0.290 |
Why?
|
| GAP-43 Protein | 1 | 2007 | 5 | 0.280 |
Why?
|
| Kidney Neoplasms | 2 | 2021 | 454 | 0.280 |
Why?
|
| Meningitis, Fungal | 1 | 2007 | 6 | 0.280 |
Why?
|
| Coccidioidomycosis | 1 | 2007 | 12 | 0.280 |
Why?
|
| Anisakiasis | 1 | 2007 | 3 | 0.270 |
Why?
|
| Central Nervous System Diseases | 2 | 2005 | 109 | 0.270 |
Why?
|
| Jejunal Diseases | 1 | 2007 | 15 | 0.270 |
Why?
|
| Tissue Array Analysis | 1 | 2007 | 140 | 0.270 |
Why?
|
| Spinal Cord Compression | 1 | 2007 | 33 | 0.270 |
Why?
|
| Aged, 80 and over | 13 | 2022 | 7112 | 0.270 |
Why?
|
| Carcinoma, Small Cell | 1 | 2007 | 42 | 0.270 |
Why?
|
| Promoter Regions, Genetic | 2 | 2024 | 1294 | 0.270 |
Why?
|
| Muscle Weakness | 1 | 2007 | 93 | 0.260 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2007 | 169 | 0.260 |
Why?
|
| Leg | 1 | 2007 | 134 | 0.260 |
Why?
|
| Choroid Plexus Neoplasms | 1 | 2006 | 18 | 0.250 |
Why?
|
| T-Lymphocytes | 4 | 2017 | 1759 | 0.250 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2023 | 293 | 0.250 |
Why?
|
| Jugular Veins | 1 | 2006 | 76 | 0.250 |
Why?
|
| Frozen Sections | 1 | 2005 | 31 | 0.240 |
Why?
|
| Cytodiagnosis | 1 | 2005 | 21 | 0.240 |
Why?
|
| Receptors, GABA | 1 | 2025 | 17 | 0.240 |
Why?
|
| Lung Neoplasms | 3 | 2017 | 1541 | 0.240 |
Why?
|
| Incidental Findings | 1 | 2005 | 130 | 0.220 |
Why?
|
| Influenza, Human | 1 | 2011 | 700 | 0.220 |
Why?
|
| Neurodegenerative Diseases | 1 | 2007 | 281 | 0.220 |
Why?
|
| DNA Repair Enzymes | 1 | 2024 | 43 | 0.220 |
Why?
|
| DNA Modification Methylases | 1 | 2024 | 51 | 0.220 |
Why?
|
| Receptors, Androgen | 1 | 2007 | 410 | 0.220 |
Why?
|
| Neoplasm Proteins | 2 | 2020 | 701 | 0.220 |
Why?
|
| Glial Fibrillary Acidic Protein | 5 | 2010 | 115 | 0.220 |
Why?
|
| TDP-43 Proteinopathies | 1 | 2024 | 15 | 0.220 |
Why?
|
| Neoplasm Metastasis | 3 | 2021 | 725 | 0.210 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2016 | 3853 | 0.210 |
Why?
|
| Cryoglobulins | 1 | 2003 | 2 | 0.210 |
Why?
|
| Positron-Emission Tomography | 1 | 2025 | 311 | 0.200 |
Why?
|
| Glioma | 4 | 2024 | 534 | 0.200 |
Why?
|
| Immunosuppressive Agents | 1 | 2007 | 672 | 0.200 |
Why?
|
| DNA Repeat Expansion | 2 | 2023 | 79 | 0.200 |
Why?
|
| Health Services Needs and Demand | 2 | 2015 | 174 | 0.200 |
Why?
|
| Amyloid beta-Peptides | 3 | 2020 | 234 | 0.200 |
Why?
|
| Cell Nucleus | 3 | 2014 | 596 | 0.190 |
Why?
|
| Thyroid Nuclear Factor 1 | 2 | 2016 | 13 | 0.190 |
Why?
|
| alpha-Synuclein | 3 | 2015 | 134 | 0.190 |
Why?
|
| S100 Proteins | 3 | 2008 | 47 | 0.190 |
Why?
|
| Neuropathology | 1 | 2022 | 7 | 0.190 |
Why?
|
| Pregnancy Complications, Neoplastic | 2 | 2017 | 66 | 0.190 |
Why?
|
| Surveys and Questionnaires | 3 | 2017 | 3983 | 0.190 |
Why?
|
| S100 Calcium-Binding Protein A4 | 1 | 2022 | 22 | 0.190 |
Why?
|
| Muscle, Skeletal | 2 | 2019 | 1042 | 0.190 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2023 | 225 | 0.180 |
Why?
|
| Referral and Consultation | 1 | 2005 | 569 | 0.180 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2024 | 493 | 0.180 |
Why?
|
| Lymphoma, B-Cell | 1 | 2003 | 148 | 0.180 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2003 | 153 | 0.180 |
Why?
|
| Inclusion Bodies | 3 | 2017 | 48 | 0.170 |
Why?
|
| Hippocampus | 2 | 2017 | 819 | 0.170 |
Why?
|
| Dementia | 2 | 2024 | 475 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2019 | 1303 | 0.170 |
Why?
|
| Limbic Encephalitis | 1 | 2020 | 4 | 0.160 |
Why?
|
| Nuclear Proteins | 3 | 2016 | 1285 | 0.160 |
Why?
|
| United States | 8 | 2017 | 11631 | 0.160 |
Why?
|
| Ganglioglioma | 2 | 2010 | 22 | 0.160 |
Why?
|
| F-Box Proteins | 1 | 2020 | 37 | 0.160 |
Why?
|
| Myositis, Inclusion Body | 1 | 2020 | 55 | 0.160 |
Why?
|
| Chorea | 1 | 2020 | 39 | 0.160 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2021 | 186 | 0.160 |
Why?
|
| Chordoma | 2 | 2010 | 19 | 0.160 |
Why?
|
| Motor Neurons | 1 | 2020 | 134 | 0.160 |
Why?
|
| X-linked Nuclear Protein | 1 | 2019 | 18 | 0.150 |
Why?
|
| Young Adult | 5 | 2016 | 9949 | 0.150 |
Why?
|
| Nerve Degeneration | 1 | 2020 | 129 | 0.150 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2017 | 499 | 0.150 |
Why?
|
| Liver Transplantation | 1 | 2007 | 1104 | 0.150 |
Why?
|
| Transcription Factors | 4 | 2016 | 2494 | 0.150 |
Why?
|
| Single-Cell Analysis | 1 | 2022 | 353 | 0.140 |
Why?
|
| Rhabdoid Tumor | 2 | 2010 | 56 | 0.140 |
Why?
|
| Protein Aggregation, Pathological | 1 | 2018 | 30 | 0.140 |
Why?
|
| Dystonia | 1 | 2020 | 173 | 0.140 |
Why?
|
| Choriocarcinoma | 1 | 2017 | 4 | 0.140 |
Why?
|
| DNA Methylation | 1 | 2024 | 1132 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2025 | 2064 | 0.140 |
Why?
|
| Calbindin 2 | 2 | 2007 | 18 | 0.130 |
Why?
|
| Infusions, Intraventricular | 1 | 2016 | 12 | 0.130 |
Why?
|
| Intracranial Aneurysm | 1 | 2017 | 85 | 0.130 |
Why?
|
| Fellowships and Scholarships | 2 | 2017 | 323 | 0.130 |
Why?
|
| Fatal Outcome | 3 | 2020 | 377 | 0.130 |
Why?
|
| Keratin-20 | 1 | 2016 | 12 | 0.130 |
Why?
|
| Keratin-7 | 1 | 2016 | 8 | 0.130 |
Why?
|
| Injections, Intravenous | 1 | 2016 | 247 | 0.130 |
Why?
|
| PAX8 Transcription Factor | 1 | 2016 | 16 | 0.120 |
Why?
|
| Uterine Neoplasms | 1 | 2017 | 112 | 0.120 |
Why?
|
| Faculty | 1 | 2017 | 104 | 0.120 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2016 | 56 | 0.120 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2016 | 34 | 0.120 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2017 | 165 | 0.120 |
Why?
|
| Aneurysm, False | 1 | 2017 | 94 | 0.120 |
Why?
|
| Cerebral Hemorrhage | 1 | 2017 | 158 | 0.120 |
Why?
|
| Synapses | 1 | 2020 | 461 | 0.120 |
Why?
|
| Mucin-1 | 2 | 2006 | 38 | 0.120 |
Why?
|
| Up-Regulation | 2 | 2020 | 879 | 0.120 |
Why?
|
| Vimentin | 2 | 2006 | 69 | 0.120 |
Why?
|
| Capsid Proteins | 1 | 2016 | 195 | 0.120 |
Why?
|
| Glioma, Subependymal | 1 | 2015 | 2 | 0.120 |
Why?
|
| Treatment Outcome | 7 | 2017 | 13020 | 0.120 |
Why?
|
| Fourth Ventricle | 1 | 2015 | 10 | 0.120 |
Why?
|
| Computer Simulation | 1 | 2018 | 699 | 0.120 |
Why?
|
| Receptors, Cell Surface | 1 | 2017 | 452 | 0.120 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 2015 | 15 | 0.120 |
Why?
|
| Multiple System Atrophy | 1 | 2015 | 18 | 0.120 |
Why?
|
| Immediate-Early Proteins | 1 | 2015 | 59 | 0.120 |
Why?
|
| Viral Matrix Proteins | 1 | 2015 | 110 | 0.120 |
Why?
|
| Astrocytes | 1 | 2018 | 270 | 0.110 |
Why?
|
| Gene Transfer Techniques | 1 | 2016 | 350 | 0.110 |
Why?
|
| Education, Continuing | 1 | 2015 | 32 | 0.110 |
Why?
|
| Membrane Transport Proteins | 1 | 2016 | 182 | 0.110 |
Why?
|
| DNA Repair | 1 | 2018 | 567 | 0.110 |
Why?
|
| Chromatin | 1 | 2018 | 521 | 0.110 |
Why?
|
| Mutation | 4 | 2019 | 6250 | 0.110 |
Why?
|
| MEDLINE | 1 | 2014 | 20 | 0.110 |
Why?
|
| Adolescent | 8 | 2017 | 20560 | 0.110 |
Why?
|
| Leadership | 1 | 2017 | 246 | 0.110 |
Why?
|
| Cerebellopontine Angle | 2 | 2011 | 8 | 0.110 |
Why?
|
| Mitochondria | 1 | 2020 | 752 | 0.110 |
Why?
|
| Needs Assessment | 1 | 2015 | 179 | 0.110 |
Why?
|
| Vision Disorders | 1 | 2016 | 217 | 0.110 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2017 | 273 | 0.110 |
Why?
|
| Brain Diseases | 1 | 2017 | 307 | 0.110 |
Why?
|
| Separase | 1 | 2014 | 29 | 0.110 |
Why?
|
| Frontal Lobe | 2 | 2005 | 120 | 0.110 |
Why?
|
| Receptor, ErbB-2 | 3 | 2017 | 549 | 0.110 |
Why?
|
| HEK293 Cells | 1 | 2016 | 796 | 0.110 |
Why?
|
| Accreditation | 1 | 2014 | 94 | 0.100 |
Why?
|
| Glycoproteins | 1 | 2016 | 377 | 0.100 |
Why?
|
| Basal Ganglia Diseases | 1 | 2013 | 26 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2016 | 1227 | 0.100 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 585 | 0.100 |
Why?
|
| Antigens, Neoplasm | 1 | 2016 | 403 | 0.100 |
Why?
|
| Nervous System | 1 | 2014 | 127 | 0.100 |
Why?
|
| SMARCB1 Protein | 2 | 2010 | 48 | 0.100 |
Why?
|
| Leiomyosarcoma | 1 | 2013 | 30 | 0.100 |
Why?
|
| Phosphoproteins | 1 | 2015 | 443 | 0.100 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2013 | 64 | 0.100 |
Why?
|
| Receptor, EphA2 | 1 | 2012 | 29 | 0.100 |
Why?
|
| Mice | 7 | 2022 | 18572 | 0.090 |
Why?
|
| Visual Acuity | 1 | 2016 | 707 | 0.090 |
Why?
|
| Giant Cells | 1 | 2012 | 35 | 0.090 |
Why?
|
| Neurology | 1 | 2014 | 118 | 0.090 |
Why?
|
| Hodgkin Disease | 2 | 2013 | 305 | 0.090 |
Why?
|
| Chromosomal Proteins, Non-Histone | 2 | 2010 | 201 | 0.090 |
Why?
|
| Spinal Cord Neoplasms | 2 | 2012 | 72 | 0.090 |
Why?
|
| Epidermal Cyst | 1 | 2011 | 18 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 2 | 2022 | 4767 | 0.090 |
Why?
|
| Animals | 8 | 2022 | 34996 | 0.090 |
Why?
|
| Melanoma | 2 | 2008 | 954 | 0.090 |
Why?
|
| Gene Regulatory Networks | 1 | 2013 | 383 | 0.090 |
Why?
|
| Point Mutation | 1 | 2012 | 350 | 0.080 |
Why?
|
| Cerebellar Diseases | 1 | 2011 | 81 | 0.080 |
Why?
|
| Carrier Proteins | 1 | 2016 | 1049 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2013 | 494 | 0.080 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2012 | 234 | 0.080 |
Why?
|
| Whipple Disease | 1 | 2010 | 6 | 0.080 |
Why?
|
| Pinealoma | 1 | 2010 | 23 | 0.080 |
Why?
|
| Carcinoma | 1 | 2013 | 300 | 0.080 |
Why?
|
| Aquaporin 1 | 1 | 2010 | 8 | 0.080 |
Why?
|
| Fetal Proteins | 1 | 2010 | 13 | 0.080 |
Why?
|
| Supratentorial Neoplasms | 1 | 2010 | 40 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2015 | 1229 | 0.080 |
Why?
|
| Central Nervous System Infections | 1 | 2010 | 22 | 0.080 |
Why?
|
| Rats | 1 | 2016 | 3620 | 0.080 |
Why?
|
| Thyroid Neoplasms | 1 | 2013 | 249 | 0.080 |
Why?
|
| Antigens, Viral | 1 | 2012 | 439 | 0.080 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2010 | 56 | 0.080 |
Why?
|
| Disease Progression | 4 | 2021 | 2228 | 0.080 |
Why?
|
| Inhibins | 1 | 2010 | 87 | 0.080 |
Why?
|
| Central Nervous System Fungal Infections | 1 | 2009 | 14 | 0.080 |
Why?
|
| Neurofibrillary Tangles | 1 | 2009 | 27 | 0.080 |
Why?
|
| Cytomegalovirus | 3 | 2017 | 263 | 0.080 |
Why?
|
| Hospitals, Urban | 1 | 2009 | 99 | 0.080 |
Why?
|
| Follow-Up Studies | 4 | 2017 | 5405 | 0.080 |
Why?
|
| Teratoma | 1 | 2010 | 130 | 0.080 |
Why?
|
| Plaque, Amyloid | 1 | 2009 | 70 | 0.080 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2009 | 31 | 0.080 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2009 | 40 | 0.080 |
Why?
|
| Mucins | 1 | 2009 | 72 | 0.080 |
Why?
|
| T-Box Domain Proteins | 1 | 2010 | 122 | 0.080 |
Why?
|
| Protein Aggregates | 2 | 2020 | 35 | 0.070 |
Why?
|
| Brain Stem Neoplasms | 1 | 2009 | 47 | 0.070 |
Why?
|
| Computational Biology | 1 | 2014 | 875 | 0.070 |
Why?
|
| Cerebral Cortex | 1 | 2012 | 482 | 0.070 |
Why?
|
| Adenocarcinoma | 2 | 2008 | 1018 | 0.070 |
Why?
|
| Antifungal Agents | 2 | 2009 | 313 | 0.070 |
Why?
|
| Aging | 1 | 2016 | 1261 | 0.070 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2010 | 236 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 2 | 2022 | 1132 | 0.070 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2008 | 31 | 0.070 |
Why?
|
| Mycoses | 1 | 2009 | 117 | 0.070 |
Why?
|
| beta Catenin | 1 | 2010 | 228 | 0.070 |
Why?
|
| Vulvar Neoplasms | 1 | 2008 | 22 | 0.070 |
Why?
|
| Exome | 1 | 2013 | 1086 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2014 | 1707 | 0.070 |
Why?
|
| Cell Differentiation | 1 | 2016 | 1975 | 0.070 |
Why?
|
| Subdural Space | 1 | 2007 | 4 | 0.070 |
Why?
|
| World Health Organization | 1 | 2008 | 119 | 0.070 |
Why?
|
| Spinal Canal | 1 | 2007 | 5 | 0.070 |
Why?
|
| Specimen Handling | 2 | 2024 | 151 | 0.070 |
Why?
|
| Laminectomy | 1 | 2007 | 24 | 0.070 |
Why?
|
| Anisakis | 1 | 2007 | 2 | 0.070 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2012 | 898 | 0.070 |
Why?
|
| Ki-67 Antigen | 1 | 2007 | 118 | 0.070 |
Why?
|
| Fishes | 1 | 2007 | 37 | 0.070 |
Why?
|
| Neoplastic Stem Cells | 1 | 2010 | 348 | 0.070 |
Why?
|
| Prognosis | 4 | 2022 | 5010 | 0.070 |
Why?
|
| Opportunistic Infections | 1 | 2007 | 80 | 0.070 |
Why?
|
| Decompression, Surgical | 1 | 2007 | 92 | 0.070 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2010 | 520 | 0.070 |
Why?
|
| Germinoma | 1 | 2007 | 32 | 0.070 |
Why?
|
| Jejunum | 1 | 2007 | 131 | 0.060 |
Why?
|
| Sclerosis | 2 | 2017 | 38 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2020 | 774 | 0.060 |
Why?
|
| Child | 6 | 2019 | 25835 | 0.060 |
Why?
|
| Recurrence | 3 | 2017 | 1458 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 3088 | 0.060 |
Why?
|
| Abscess | 1 | 2007 | 140 | 0.060 |
Why?
|
| Cohort Studies | 5 | 2017 | 5153 | 0.060 |
Why?
|
| Skull Base | 1 | 2006 | 51 | 0.060 |
Why?
|
| Trinucleotide Repeat Expansion | 1 | 2007 | 128 | 0.060 |
Why?
|
| Pituitary Gland, Posterior | 1 | 2005 | 5 | 0.060 |
Why?
|
| CD56 Antigen | 1 | 2005 | 29 | 0.060 |
Why?
|
| Huntington Disease | 1 | 2007 | 144 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 764 | 0.060 |
Why?
|
| Neurosurgical Procedures | 3 | 2016 | 316 | 0.060 |
Why?
|
| Immunocompromised Host | 1 | 2007 | 308 | 0.060 |
Why?
|
| Antibodies | 1 | 2007 | 368 | 0.060 |
Why?
|
| Antigens, CD34 | 1 | 2005 | 109 | 0.060 |
Why?
|
| Parietal Lobe | 1 | 2005 | 48 | 0.060 |
Why?
|
| tau Proteins | 1 | 2007 | 237 | 0.060 |
Why?
|
| Dermatofibrosarcoma | 1 | 2005 | 18 | 0.060 |
Why?
|
| Child, Preschool | 4 | 2015 | 14862 | 0.050 |
Why?
|
| Gliosarcoma | 1 | 2004 | 10 | 0.050 |
Why?
|
| Infant | 3 | 2019 | 13198 | 0.050 |
Why?
|
| Organelles | 1 | 2003 | 23 | 0.050 |
Why?
|
| Retrospective Studies | 5 | 2017 | 17371 | 0.050 |
Why?
|
| Phenytoin | 1 | 2003 | 60 | 0.050 |
Why?
|
| Dura Mater | 1 | 2002 | 26 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2003 | 399 | 0.050 |
Why?
|
| Medulloblastoma | 1 | 2007 | 571 | 0.050 |
Why?
|
| Dexamethasone | 1 | 2003 | 273 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2003 | 265 | 0.050 |
Why?
|
| Amygdala | 1 | 2022 | 85 | 0.040 |
Why?
|
| Kidney Pelvis | 1 | 2021 | 46 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2022 | 118 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2017 | 998 | 0.040 |
Why?
|
| Urothelium | 1 | 2021 | 60 | 0.040 |
Why?
|
| Motor Cortex | 1 | 2021 | 85 | 0.040 |
Why?
|
| Survival Rate | 2 | 2017 | 2187 | 0.040 |
Why?
|
| Anticonvulsants | 1 | 2003 | 390 | 0.040 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2020 | 47 | 0.040 |
Why?
|
| Mice, SCID | 2 | 2012 | 604 | 0.040 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2020 | 61 | 0.040 |
Why?
|
| Urinary Bladder | 1 | 2021 | 257 | 0.040 |
Why?
|
| Caspase 3 | 1 | 2020 | 141 | 0.040 |
Why?
|
| Time Factors | 1 | 2010 | 6457 | 0.040 |
Why?
|
| Autoantigens | 1 | 2020 | 109 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2018 | 2687 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2020 | 180 | 0.040 |
Why?
|
| Gadolinium | 2 | 2010 | 116 | 0.040 |
Why?
|
| Cell Death | 1 | 2020 | 243 | 0.040 |
Why?
|
| Pregnancy | 2 | 2017 | 7568 | 0.040 |
Why?
|
| Electronic Health Records | 2 | 2018 | 802 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2005 | 1313 | 0.040 |
Why?
|
| Enzyme Activation | 1 | 2020 | 618 | 0.040 |
Why?
|
| Intranuclear Inclusion Bodies | 1 | 2018 | 13 | 0.040 |
Why?
|
| RNA-Binding Protein FUS | 1 | 2018 | 20 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2017 | 3422 | 0.040 |
Why?
|
| Proteins | 1 | 2023 | 1064 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2018 | 87 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 2018 | 341 | 0.030 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2017 | 52 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2018 | 88 | 0.030 |
Why?
|
| Neostriatum | 1 | 2017 | 11 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2019 | 241 | 0.030 |
Why?
|
| Autoimmune Diseases | 1 | 2020 | 273 | 0.030 |
Why?
|
| Mitosis | 1 | 2018 | 201 | 0.030 |
Why?
|
| Cerebral Angiography | 1 | 2017 | 106 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 688 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2019 | 343 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2018 | 440 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2019 | 222 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 578 | 0.030 |
Why?
|
| Brain Chemistry | 1 | 2017 | 118 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2020 | 459 | 0.030 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2021 | 539 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 503 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 1047 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 285 | 0.030 |
Why?
|
| Protein Binding | 1 | 2020 | 1735 | 0.030 |
Why?
|
| Biopsy | 2 | 2010 | 1289 | 0.030 |
Why?
|
| Breast Neoplasms | 2 | 2005 | 2683 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2014 | 1230 | 0.030 |
Why?
|
| Lewy Body Disease | 1 | 2015 | 21 | 0.030 |
Why?
|
| Patient Care Management | 1 | 2015 | 66 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2017 | 275 | 0.030 |
Why?
|
| Adenoviridae | 1 | 2017 | 596 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 2017 | 675 | 0.030 |
Why?
|
| Health Information Management | 1 | 2014 | 6 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2003 | 1577 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2018 | 1615 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2022 | 1598 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2020 | 2453 | 0.030 |
Why?
|
| Forecasting | 1 | 2015 | 373 | 0.030 |
Why?
|
| RNA-Binding Proteins | 1 | 2018 | 605 | 0.030 |
Why?
|
| International Cooperation | 1 | 2014 | 166 | 0.030 |
Why?
|
| Marketing of Health Services | 1 | 2013 | 25 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2015 | 392 | 0.030 |
Why?
|
| Neuroglia | 1 | 2015 | 214 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2014 | 144 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2017 | 571 | 0.020 |
Why?
|
| GATA3 Transcription Factor | 1 | 2012 | 43 | 0.020 |
Why?
|
| K562 Cells | 1 | 2012 | 97 | 0.020 |
Why?
|
| Risk Factors | 2 | 2022 | 10912 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2012 | 147 | 0.020 |
Why?
|
| Carcinoma, Papillary | 1 | 2013 | 93 | 0.020 |
Why?
|
| Retroviridae | 1 | 2012 | 194 | 0.020 |
Why?
|
| Cerebrum | 1 | 2012 | 37 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2012 | 241 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2014 | 611 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2012 | 294 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2012 | 241 | 0.020 |
Why?
|
| Cell Separation | 1 | 2012 | 227 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 242 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2012 | 470 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2012 | 303 | 0.020 |
Why?
|
| Craniotomy | 1 | 2011 | 105 | 0.020 |
Why?
|
| Apoptosis | 1 | 2017 | 1904 | 0.020 |
Why?
|
| CD4 Antigens | 1 | 2010 | 56 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2010 | 102 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2017 | 2512 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2012 | 539 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 387 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2012 | 619 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 830 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2012 | 475 | 0.020 |
Why?
|
| Mice, Inbred ICR | 1 | 2010 | 152 | 0.020 |
Why?
|
| Cytomegalovirus Infections | 1 | 2012 | 225 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 1126 | 0.020 |
Why?
|
| Tumor Escape | 1 | 2010 | 64 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 806 | 0.020 |
Why?
|
| Pedigree | 1 | 2013 | 1725 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 663 | 0.020 |
Why?
|
| Periodontics | 1 | 1988 | 3 | 0.020 |
Why?
|
| Students, Dental | 1 | 1988 | 8 | 0.020 |
Why?
|
| Education, Dental | 1 | 1988 | 9 | 0.020 |
Why?
|
| Surgery, Oral | 1 | 1988 | 7 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2010 | 249 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2010 | 219 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 775 | 0.020 |
Why?
|
| Curriculum | 1 | 2014 | 765 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2010 | 288 | 0.020 |
Why?
|
| Attitude | 1 | 1988 | 120 | 0.020 |
Why?
|
| Gene Expression | 1 | 2012 | 1564 | 0.020 |
Why?
|
| Reoperation | 1 | 2011 | 853 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 1085 | 0.020 |
Why?
|
| Teaching | 1 | 1988 | 200 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2010 | 795 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 1807 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2010 | 761 | 0.020 |
Why?
|
| Huntingtin Protein | 1 | 2007 | 64 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2019 | 4725 | 0.020 |
Why?
|
| Survival | 1 | 2005 | 19 | 0.010 |
Why?
|
| Contrast Media | 1 | 2009 | 508 | 0.010 |
Why?
|
| Ultrasonography, Mammary | 1 | 2005 | 33 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2012 | 3698 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2009 | 778 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2010 | 3062 | 0.010 |
Why?
|
| Synaptophysin | 1 | 2003 | 20 | 0.010 |
Why?
|
| Neurofilament Proteins | 1 | 2003 | 36 | 0.010 |
Why?
|
| Tubulin | 1 | 2003 | 76 | 0.010 |
Why?
|
| Meninges | 1 | 2002 | 22 | 0.010 |
Why?
|
| Histiocytosis, Sinus | 1 | 2002 | 34 | 0.010 |
Why?
|
| Sarcoidosis | 1 | 2002 | 58 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2012 | 6540 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2005 | 989 | 0.010 |
Why?
|
| Psychometrics | 1 | 2005 | 693 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2005 | 1502 | 0.010 |
Why?
|
| England | 1 | 1988 | 63 | 0.000 |
Why?
|